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Abstract
Background: Since use of non-steroidal anti-inflammatory drugs (NSAIDs) during pregnancy is common, small increases in
the risk of birth defects may have significant implications for public health. Results of human studies on the teratogenic risks
of NSAIDs are inconsistent. Therefore, we evaluated the risk of selected birth defects after prenatal exposure to prescribed
and over-the-counter NSAIDs.
Methods and Findings: We used data on 69,929 women enrolled in the Norwegian Mother and Child Cohort Study
between 1999 and 2006. Data on NSAID exposure were available from a self-administered questionnaire completed around
gestational week 17. Information on pregnancy outcome was obtained from the Medical Birth Registry of Norway. Only
birth defects suspected to be associated with NSAID exposure based upon proposed teratogenic mechanisms and previous
studies were included in the multivariable logistic regression analyses. A total of 3,023 women used NSAIDs in gestational
weeks 0–12 and 64,074 women did not report NSAID use in early pregnancy. No associations were observed between
overall exposure to NSAIDs during pregnancy and the selected birth defects separately or as a group (adjusted odds ratio
0.7, 95% confidence interval 0.4–1.1). Associations between maternal use of specific types of NSAIDs and the selected birth
defects were not found either, although an increased risk was seen for septal defects and exposure to multiple NSAIDs
based on small numbers (2 exposed cases; crude odds ratio 3.9, 95% confidence interval 0.9–15.7).
Conclusions: Exposure to NSAIDs during the first 12 weeks of gestation does not seem to be associated with an increased
risk of the selected birth defects. However, due to the small numbers of NSAID-exposed infants for the individual birth
defect categories, increases in the risks of specific birth defects could not be excluded.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently
used for their analgesic, antipyretic, and anti-inflammatory effects.
They are among the most common drugs prescribed in the first
trimester of pregnancy [1], and over-the-counter use of NSAIDs is
also very widespread during pregnancy with prevalence estimates
up to 19% [2,3]. NSAIDs act as an inhibitor of cyclooxygenases
(COXs), which catalyze the conversion of arachidonic acid to
prostaglandins. Two isoforms of this enzyme have been identified:
COX-1 and COX-2. The anti-inflammatory effects of NSAIDs
are the result of COX-2 inhibition, while the adverse effects of
non-selective NSAIDs are mainly due to the inhibition of COX-1
[4]. Results of animal studies suggest that COX-1 inhibition also
may lead to cardiac, midline, and diaphragm defects [5,6].
Since NSAID use during pregnancy is common, even small
increases in the risk of birth defects may have significant implications
for public health. Results of human studies on the teratogenic risks of
first trimester NSAID use are inconsistent. Recent epidemiologic
investigations showed an increased risk of congenital heart defects,
especially cardiac septal defects, and orofacial clefts [7–9], while
others did not find such effects [3,10]. The aim of this study was to
evaluate associations between maternal NSAID use during the first
12 weeks of gestation and the occurrence of selected birth defects
using data from the Norwegian Mother and Child Cohort Study
(MoBa), which includes information on both prescribed and over-the-
counter NSAID use.
Methods
Ethics Statement
The study was approved by the Regional Committee for
Medical Research Ethics and the Norwegian Data Inspectorate.
All participants gave their written informed consent.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22174
Study population and data collection
MoBa is a prospective cohort study conducted by the
Norwegian Institute of Public Health, which enrolled women in
early pregnancy between 1999 and 2007. The objective of this
study is to estimate the effects of a wide range of exposures during
pregnancy on pregnancy outcome and maternal and child health
[11]. During the enrollment period, participating hospitals and
maternity units weekly provided lists of names and addresses of
pregnant women living in Norway who requested routine
ultrasound examination. The Norwegian Institute of Public Health
subsequently sent these women a postal invitation to participate in
MoBa, which included an information brochure, an informed
consent form, and the first questionnaire, together with appoint-
ments for routine ultrasound scanning in gestational weeks 13–17.
In this questionnaire, questions were asked about sociodemo-
graphic characteristics, maternal health, medication use, lifestyle
factors, and occupational exposures during the 6 months prior to
pregnancy and during the current pregnancy. The overall
participation rate was 43.5% for pregnancies invited in MoBa
[12]. To obtain information on pregnancy outcome, data from
MoBa were linked to records in the Medical Birth Registry of
Norway (MBRN) using the women’s personal identification
number. MBRN data are obtained by mandatory, standardized
forms filled out by midwives, obstetricians, and/or pediatricians,
and include detailed medical information regarding the health of
both mother and newborn originating from medical records. All
births that take place in Norway after gestational week 16 (after
week 12 from 2002 onwards), including fetal deaths and elective
terminations of pregnancy, are recorded in the MBRN [13]. For
the current study, data were available for women enrolled in the
period 1999–2006.
Exposure and outcome definitions
Information on the type and timing of both prescribed and
over-the-counter NSAID use was available from the questionnaire.
If a woman reported use of an NSAID in the six months before or
during pregnancy, she could specify five exposure windows: before
pregnancy, gestational weeks 0–4, 5–8, 9–12, and 13+ (until
completion of the first MoBa questionnaire). We defined NSAID
exposure as use of any NSAID (Anatomical Therapeutic
Classification code M01A or N02BA [14]) during gestational
weeks 0–12. Women were considered non-exposed if they did not
report use of any NSAIDs during pregnancy in the first MoBa
questionnaire. In addition, the women were asked to report the
number of days NSAIDs were taken. However, this question was
completed by a minority of women and during the exploratory
data analyses the data appeared to be highly unreliable. Therefore,
they were not included in this study.
Only birth defects diagnosed by pediatricians and/or geneticists
in the first week after birth or while the infants were in the hospital
during their first year of life are included in the MBRN records.
Birth defects are coded according to the International Classification of
Diseases, 10th Revision (ICD-10) [15]. For this study, the outcome of
interest was the presence of major birth defects that may result
from NSAID exposure during pregnancy based upon proposed
teratogenic mechanisms and previous epidemiologic studies [16].
These selected birth defects (ICD-10 code) included neural tube
defects (Q00, Q01, and Q05), congenital heart defects, subdivided
into conotruncal heart defects (Q20.0, Q20.1, Q20.3, Q21.3,
Q21.4, and Q25.5–Q25.7 with Q21.0) and septal defects (Q21.0–
Q21.2 and Q21.4), orofacial clefts (Q35–Q37), esophageal defects
(Q39), anorectal malformations (Q42), diaphragmatic hernia
(Q79.0), abdominal wall defects (Q79.2 and Q79.3), and amniotic
bands (Q79.80). For classification of cases into isolated (no other
major unrelated birth defect) and multiple birth defects (more than
one unrelated major birth defect), the guidelines reported by
Rasmussen et al were followed [17]. Infants without any major
birth defect were considered unaffected.
Statistical analysis
Our study population consisted of all women who completed
the first MoBa questionnaire between 1999 and 2006 for whom
data on pregnancy outcome from the MBRN were available
(n = 69,929). Mothers with pre-existing diabetes were excluded
from the analyses because of the known association between this
condition and birth defects [18,19]. Case infants with chromo-
somal abnormalities and mothers with multiple gestations or
missing data on the timing of NSAID use (before or during
pregnancy) were excluded as well.
Crude results were calculated as odds ratios (ORs) with 95%
confidence intervals (CIs). We performed multivariable logistic
regression analyses using a complete case analysis approach to
estimate the risk of selected birth defects associated with NSAID
exposure during the first 12 weeks of gestation, adjusted for
maternal age at delivery (in years), maternal education (12 years or
less vs. more than 12 years), parity (no previous live births vs. one
or more previous live births), presence or absence of a history of
miscarriages, stillbirths, or induced abortions, prepregnancy body-
mass index (weight in kilograms divided by the square of height in
meters; less than 25 vs. 25 or more), any maternal folic acid use
from 4 weeks before pregnancy through week 8 of gestation, and
fever and any maternal smoking during gestational weeks 0–12.
Adjusted ORs were only calculated if at least three exposed cases
were available. We used the same potential confounder set in all
models, except when small numbers or a relatively high proportion
of missing values ($10% in either the group of affected or
unaffected infants) prevented us from including one or more co-
variables. In secondary analyses, we performed crude and adjusted
analyses to assess the associations between the different types of
NSAIDs (non-selective NSAIDs, acetic acid derivatives, and
propionic acid derivatives) and four specific NSAIDs (diclofenac,
ibuprofen, naproxen, and aspirin) and the occurrence of the
selected birth defects. We also evaluated the effects of exposure to
multiple NSAIDs during gestational weeks 0–12 on the risk of the
selected birth defects. Additional analyses were performed on time
window-specific exposure to NSAIDs. In sensitivity analyses, we
assessed whether restricting the analyses to women without pre-
existing diseases (asthma, hypertension, or epilepsy) or to infants
with isolated defects only changed the effect estimates. Further-
more, we determined whether clustering due to enrollment in
MoBa of multiple pregnancies by one woman influenced the
results by including primiparae only, as we did not have
information on the number of times a particular woman
participated in MoBa. Finally, we estimated the potential effect
of bias resulting from the relatively low response rate on the
results. All statistical analyses were performed using SPSS version
17.0 for Windows (SPSS Inc., Chicago, IL.).
Results
Of the 69,929 pregnant women with complete information,
2,038 had one or several of the following exclusion criteria: pre-
existing diabetes (n = 390), diagnosis of a chromosomal abnormal-
ity (n = 121), multiple gestation (n = 1,290), and missing informa-
tion on the timing of NSAID use (n = 256). Consequently, the final
study population consisted of 67,891 women. A total of 6,972
(10.3%) women reported use of an NSAID in the 6 months before
pregnancy and 3,023 (4.5%) women reported NSAID use during
Prenatal NSAID Exposure and Birth Defects
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the first 12 weeks of gestation. Women who reported NSAID use in
gestational weeks 13+ only (n = 569) and women who did not report
the exact timing of NSAID use during pregnancy (n = 225) were
omitted from further analyses. Ibuprofen was most commonly used
(3.4%), followed by aspirin (0.5%), diclofenac (0.3%), and naproxen
(0.2%). Most NSAID-using women used one NSAID (97.2%).
Women who used NSAIDs during gestational weeks 0–12 were less
likely to have more than 12 years of education, to be married or
cohabiting, and to have had a previous live birth compared to non-
using women (Table 1). NSAID-users were more likely than women
who did not use NSAIDs during pregnancy to have had a previous
miscarriage, stillbirth, or induced abortion, and to be overweight or
obese. However, the absolute differences between the two groups
were rather small.
The prevalence of all major birth defects was 2.7% in our
cohort (80 affected NSAID-exposed and 1,730 non-exposed
infants). The selected birth defects were diagnosed in 638 infants
(1.0%). A total of 18 infants had a neural tube defect (including 2
with anencephaly, 2 with encephalocele, and 15 with spina bifida),
435 a congenital heart defect (including 38 with conotruncal
defect, 289 with ventricular septal defect, 156 with atrial septal
defect, and 7 with atrioventricular septal defect), 134 an orofacial
cleft (including 44 with cleft palate and 90 with cleft lip with or
without cleft palate), 20 an esophageal defect, 16 an anorectal
malformation, 11 a diaphragmatic defect, and 21 an abdominal
wall defect (including 6 with omphalocele and 15 with gastroschi-
sis). No infants in our study cohort were diagnosed with amniotic
bands. Of the infants with selected birth defects, 42 infants (6.6%)
Table 1. Characteristics of women who used and did not use non-steroidal anti-inflammatory drugs (NSAIDs) in gestational weeks
0–12.a
Characteristic Subcategory NSAID used (n=3,023) No NSAID used (n=64,074)
Age at delivery ,20 y 42 (1.4) 689 (1.1)
20–29 y 1,320 (43.7) 28,406 (44.3)
30–39 y 1,607 (53.2) 33,774 (52.7)
$40 y 54 (1.8) 1,205 (1.9)
Education ,10 y 96 (3.2) 1,989 (3.1)
10–12 y 1,134 (37.5) 21,575 (33.7)
.12 y 1,639 (54.2) 37,109 (57.9)
Other 62 (2.1) 1,091 (1.7)
Missing 92 (3.0) 2,310 (3.6)
Married/cohabiting Married/cohabiting 2,862 (94.7) 61,541 (96.0)
Other 143 (4.7) 2,232 (3.5)
Missing 18 (0.6) 301 (0.5)
Parity 0 previous live births 1,393 (46.1) 27,732 (43.3)
$1 previous live births 1,629 (53.9) 36,337 (56.7)
Missing 1 (0.0) 5 (0.0)
Previous miscarriages, stillbirth,
or induced abortions
None 1,874 (62.0) 41,175 (64.3)
Miscarriage or stillbirth 572 (18.9) 11,661 (18.2)
Induced abortion 401 (13.3) 7,190 (11.2)
Induced abortion and miscarriage or stillbirth 123 (4.1) 2,347 (3.7)
Missing 53 (1.8) 1,701 (2.7)
Prepregnancy body-mass indexb Underweight 74 (2.4) 1,947 (3.0)
Normal weight 1,795 (59.4) 40,534 (63.2)
Overweight 684 (22.6) 13,782 (21.5)
Obese 398 (13.2) 5,917 (9.2)
Missing 72 (2.4) 1,894 (3.0)
Any folic acid usec Yes 1,916 (63.4) 40,611 (63.4)
No 1,107 (36.6) 23,463 (36.6)
Pregnancy outcome Live birth, still alive 2,993 (99.0) 63,622 (99.3)
Live birth, died during follow-up 10 (0.3) 158 (0.2)
Stillbirth 19 (0.6) 271 (0.4)
Induced abortion 1 (0.0) 23 (0.0)
aData from the Norwegian Mother and Child Cohort Study, 1999–2006. All data are presented as a number (%). Percentages may not add up to 100% due to rounding.
bThe body-mass index is the weight in kilograms divided by the square of the height in meters: underweight: ,18.5 kg/m2, normal weight: 18.5–24.9 kg/m2;
overweight: 25.0–29.9 kg/m2, obese: $30 kg/m2.
cFolic acid use is reported from the 4 weeks prior to pregnancy through week 8 of gestation.
doi:10.1371/journal.pone.0022174.t001
Prenatal NSAID Exposure and Birth Defects
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22174
were classified as having multiple defects. Our study cohort
included 65,287 infants without a major birth defect.
Table S1 shows the characteristics of the 23 infants exposed to
NSAIDs in the first 12 weeks of gestation who had any of the
selected birth defects. The maternal age at delivery ranged from
25 to 35 years. A total of 21 infants were live born at gestational
ages ranging from 34 to 42 weeks, one woman had a miscarriage
at 18 weeks of gestation, and one infant was stillborn at a
gestational age of 39 weeks. All but five of these infants were
exposed to other medications during pregnancy in addition to
NSAIDs, of which one infant was exposed to a drug generally
considered teratogenic (podophyllotoxin).
The crude and adjusted odds ratios for overall NSAID exposure
and the selected birth defects are shown in Table 2. Any NSAID
use during the first 12 weeks of gestation was not associated with
all selected birth defects as a group (adjusted OR 0.7 (95% CI 0.4–
1.1)) nor with any of the birth defect categories, including any
congenital heart defects (adjusted OR 0.9 (95% CI 0.5–1.4)), septal
defects (adjusted OR 0.8 (95% CI 0.5–1.4)), ventricular septal
defects (adjusted OR 0.7 (95% CI 0.4–1.4)), and atrial septal
defects (adjusted OR 1.1 (95% CI 0.5–2.3)). For the other groups
of birth defects, there were too few exposed cases to reliably
estimate adjusted odds ratios. A crude OR of 0.2 (95% CI 0.0–1.1)
was seen for orofacial clefts based on one exposed case. Analyses
for the three exposure time-windows assessed in the questionnaire
separately did not alter these results (Table 3), although we saw a
slightly increased risk for atrial septal defects after NSAID
exposure in gestational weeks 5–8 (adjusted OR 1.6 (95% CI
0.7–3.9)).
We conducted several secondary analyses to evaluate the effects
of exposure to different types of NSAIDs on the occurrence of the
selected birth defects (Table 4). Restricting the exposed group to
infants exposed to non-selective NSAIDs (excluding infants
exposed to coxibs only) did not change the results of the primary
analyses. No associations were observed between the selected birth
defects as a group and exposure to acetic acid derivatives (1
exposed case), propionic acid derivatives (adjusted OR 0.7 (95%
CI 0.4–1.2)), aspirin (adjusted OR 1.1 (95% CI 0.4–3.5)), or
multiple NSAIDs (crude OR 2.5 (95% CI 0.6–10.1)). However, we
found an association between exposure to multiple NSAIDs during
gestational weeks 0–12 and congenital heart defects (crude OR 3.7
(95% CI 0.9–14.9)), in particular septal defects (crude OR 3.9
(95% CI 0.9–15.7)), but this observation was based on only 2
exposed case infants. We did not find associations between any of
the other NSAID subgroups and congenital heart defects or septal
defects.
The detailed results of the sensitivity analyses are shown in
Appendix S1. Analyses restricted to women without pre-existing
diseases did not alter the results of the primary analyses, nor did
restricting the analyses to affected infants with isolated birth
defects only. Restricting the primary analyses to primiparae to
estimate the effect of clustering due to enrollment in MoBa of
multiple pregnancies by one woman did not change the effect
estimates substantially, but it did decrease precision. The
sensitivity analysis to estimate the potential bias resulting from
the relatively low response rate indicated that selective participa-
tion of mothers of either exposed, non-exposed, affected, or
unaffected infants did not change the effect estimates of the
primary analysis. Only in the unlikely event that one of the four
exposure-outcome groups was far more likely to participate in
MoBa than the other three groups, the NSAID-birth defect
associations observed could have been biased due to selection.
Table 2. Associations between maternal use of non-steroidal anti-inflammatory drugs (NSAIDs) in gestational weeks 0–12 and
selected birth defects.a
NSAID used
(n=3,023)
No NSAID used
(n=64,074)
Odds ratio
(95% CI)
Birth defect Subcategory 1 Subcategory 2 n (%) n (%) Crude Adjustedb
No major birth defects 2,943 (97.4) 62,344 (97.3) Reference Reference
All selected birth defects 23 (0.8) 615 (1.0) 0.8 (0.5–1.2) 0.7 (0.4–1.1)
Neural tube defects 1 (0.0) 17 (0.0) 1.2 (0.2–9.4) –
Congenital heart defects 20 (0.7) 415 (0.6) 1.0 (0.7–1.6) 0.9 (0.5–1.4)
Conotruncal heart
defects
2 (0.1) 36 (0.1) 1.2 (0.3–4.9) –
Septal defects 18 (0.6) 394 (0.6) 1.0 (0.6–1.6) 0.8 (0.5–1.4)
Ventricular septal defect 11 (0.4) 278 (0.4) 0.8 (0.5–1.5) 0.7 (0.4–1.4)
Atrial septal defect 8 (0.3) 148 (0.2) 1.1 (0.6–2.3) 1.1 (0.5–2.3)c
Orofacial clefts 1 (0.0) 133 (0.2) 0.2 (0.0–1.1) –
Esophageal defects 0 (0.0) 20 (0.0) – –
Anorectal malformations 1 (0.0) 15 (0.0) 1.4 (0.2–10.7) –
Diaphragmatic hernia 0 (0.0) 11 (0.0) – –
Abdominal wall defects 0 (0.0) 21 (0.0) – –
Amniotic bands 0 (0.0) 0 (0.0) – –
aData from the Norwegian Mother and Child Cohort Study, 1999–2006. Infants with multiple selected birth defects were included in all relevant outcome categories.
Adjusted analyses were performed if at least three exposed cases were available.
bAdjusted for maternal age at delivery, education, parity, history of miscarriages, stillbirths, or induced abortions, prepregnancy body-mass index, folic acid use, fever,
and smoking.
cAdjusted for maternal age at delivery, parity, prepregnancy body-mass index, folic acid use, and smoking.
doi:10.1371/journal.pone.0022174.t002
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Discussion
In this large prospective cohort study, we did not find
associations between exposure to any NSAID in the first 12 weeks
of gestation and the occurrence of birth defects such as congenital
heart defects and orofacial clefts, which were selected based upon
results of previous animal and epidemiologic studies and the
proposed teratogenic mechanism of NSAIDs. However, we did
observe a non-statistically significantly increased risk of septal
defects after exposure to multiple NSAIDs in the first 12 weeks of
gestation. Furthermore, it should be kept in mind that NSAIDs
have been associated with spontaneous abortions [10,20] and that
they are contraindicated during the third trimester of pregnancy
due to an increased risk of premature closure of the ductus
arteriosus [21,22].
Although NSAID use during pregnancy is prevalent, epidemi-
ologic studies on the teratogenic risks are relatively sparse. Recent
case-control studies, which may be prone to recall bias, showed
possible associations between NSAID exposure and ventricular
septal defects [23], amniotic bands [24], and gastroschisis [25].
Two cohort studies using data from registries, of which one used
reports from the first prenatal care visit and the other lacked
information on compliance and over-the-counter use of NSAIDs,
generally found no increased risks of birth defects after NSAID
exposure [7,10], but associations with congenital heart defects and
orofacial clefts were reported in the former [7]. A third pregnancy
register showed increased risks of any birth defect and of septal
defects in particular among infants of women who filled a
prescription for NSAIDs in the first trimester [9]. In a recent study
which used follow-up data of women who contacted Teratology
Information Services, an increased risk of major birth defects after
exposure to diclofenac in gestational weeks 5–14 could not be
excluded (crude OR 2.5 (95% CI 0.9–6.6)) [26]. To our
knowledge, the current study, using data collected in the
Norwegian Mother and Child Cohort Study, is the first
prospective cohort study to evaluate the teratogenic risk of both
prescribed and over-the-counter NSAIDs, thereby avoiding
differential misclassification by the outcome of interest often found
in retrospective studies.
In secondary analyses, we observed a possible association
between exposure to multiple NSAIDs and septal defects with two
(2.3%) of the exposed infants being diagnosed with either a
ventricular or an atrial septal defect. This finding was based on
very small numbers, but there are several reasons why this finding
might indicate a truly increased risk. First, all outcomes of interest,
including septal defects, were selected based on biologic
plausibility. Secondly, mothers of exposed cases used a combina-
tion of either ibuprofen and ketoprofen or ibuprofen and
diclofenac, which all inhibit COX-1 by more than 60% when
COX-2 is inhibited by 80% [27]. Animal studies indicate that
especially NSAIDs with a high COX-1/COX-2 ratio may cause
birth defects [5], in particular since COX-1 is expressed in rat
embryos during cardiovascular development [28]. Finally, both
animal and human studies have indicated an increased risk of
septal defects after prenatal NSAID exposure [9,20,29]. However,
as cardiac septation takes place between weeks 4 and 7 of
development [30], exposure did not occur during the etiologically
relevant period for one of the exposed cases (Table S1). Therefore,
these results should be interpreted with caution and confirmation
by other studies is warranted.
The absence of associations between maternal use of NSAIDs
during pregnancy and the occurrence of the selected birth defects
may partly be due to the relatively low prevalence of exposure in
this cohort (4.5%). Studies conducted in the U.S. found much
higher prevalence estimates of NSAID use during the first
trimester up to approximately 19% [2,3]. Comparable European
data are lacking, but recent reports indicate that NSAID use
during pregnancy may be less prevalent in European countries
compared to the U.S. [31,32], especially since NSAIDs are
contraindicated in the first and third trimester of pregnancy. In a
study using data from the Norwegian Prescription Database, 2.0%
Table 4. Secondary analyses of the risk of selected birth defects among infants with exposure to non-steroidal anti-inflammatory
drugs (NSAIDs) in gestational weeks 0–12.a
Any selected birth defect Congenital heart defect Septal defects
NSAID
exposure Subcategory Total n n (%)
Adjusted odds
ratio (95% CI)b n (%)
Adjusted odds
ratio (95% CI)b n (%)
Adjusted odds
ratio (95% CI)b
None 64,074 615 (1.0) Reference 415 (0.6) Reference 394 (0.6) Reference
Non-selective
NSAIDs
2,964 23 (0.8) 0.7 (0.4–1.1) 20 (0.7) 0.9 (0.5–1.5) 18 (0.6) 0.8 (0.5–1.4)
Acetic acid
derivatives
189 1 (0.5) – 1 (0.5) – 1 (0.5) –
Diclofenac 169 1 (0.6) – 1 (0.6) – 1 (0.6) –
Propionic acid
derivatives
2,425 19 (0.8) 0.7 (0.4–1.2)c 16 (0.7) 0.8 (0.5–1.4) 14 (0.6) 0.7 (0.4–1.3)
Ibuprofen 2,276 19 (0.8) 0.8 (0.5–1.3)c 16 (0.7) 0.9 (0.5–1.5) 14 (0.6) 0.7 (0.4–1.4)
Naproxen 166 0 (0.0) – 0 (0.0) – 0 (0.0) –
Aspirin 307 3 (1.0) 1.1 (0.4–3.5)d 3 (1.0) 1.6 (0.5–5.2)d 3 (1.0) 1.7 (0.6–5.4)d
Multiple NSAIDs 86 2 (2.3) – 2 (2.3) – 2 (2.3) –
aData from the Norwegian Mother and Child Cohort Study, 1999–2006. Infants with multiple selected birth defects were included in all relevant outcome categories.
Adjusted analyses were performed if at least three exposed cases were available.
bAdjusted for maternal age at delivery, education, parity, history of miscarriages, stillbirths, or induced abortions, prepregnancy body-mass index, folic acid use, fever,
and smoking.
cAdjusted for maternal age at delivery, education, parity, history of miscarriages, stillbirths, or induced abortions, folic acid use, fever, and smoking.
dAdjusted for maternal age at delivery, education, parity, prepregnancy body-mass index, and folic acid use.
doi:10.1371/journal.pone.0022174.t004
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of women filled at least one NSAID prescription in the first
trimester of pregnancy [33]. Therefore, we believe that the
prevalence of NSAID use during the first 12 weeks of gestation
found in our study population is accurate. However, the small
number of NSAID-exposed infants for the individual birth defect
categories remains a limitation, which made lumping of birth
defects necessary for power purposes, which, in turn, may have
masked true associations between prenatal NSAID exposure and
specific birth defects.
The main strength of this study is its longitudinal design which
features prospective ascertainment of NSAID use and other
covariate information obtained at a median of 17 weeks of
gestation. However, as MoBa has a relatively low participation
rate (43.5%), selection bias may have occurred. A recent non-
response study showed that the prevalence estimates of several
exposures and birth outcomes are biased in MoBa, but that
estimates of exposure-outcome associations are not biased due to
self-selection [12]. Similar results were obtained from a compa-
rable cohort study conducted in Denmark [34]. In addition, the
sensitivity analyses showed that selective participation on either
exposure or disease status of the infant did not influence our effect
estimates. The only scenario in the sensitivity analyses that affected
our NSAID-birth defect risk estimates was when one of the four
exposure-outcome groups was more likely to participate than the
other three groups, but this is highly unlikely in a prospective
cohort study. Therefore, we feel that our results on the associations
between prenatal NSAID exposure and selected birth defects are
not biased by the low participation rate.
Non-differential misclassification of the exposure status may
have occurred since data on NSAID use were collected using self-
administered questionnaires. In addition, there might be a chance
that the lack of an increased risk of the selected birth defects in
NSAID-exposed infants is due to the inability to separate
occasional users from the more frequent or continuous users.
Confounding by indication cannot be excluded completely either,
although restricting our analyses to women without pre-existing
diseases did not change the results of the primary analyses, in
which fever in the first 12 weeks of gestation was also included as a
potential confounder.
Several validation studies have been conducted regarding the
accuracy of the MBRN, which showed that the ascertainment of
congenital malformations varies according to the type of defect
and its severity. For the years 2001–2005, 82% of clinically verified
cases of Down syndrome were recorded in the registry [35].
Overall, 71% of cases with severe isolated cleft palate were
reported, whereas as little as 11% of cases with mild cleft palate
were recorded [36]. The registration of cardiovascular malforma-
tions in the MBRN has not been validated nor confirmed by a
geneticist or dysmorphologist. Therefore, misclassification of the
outcomes of interest may have occurred in the current study, but
we do not expect the ascertainment rates to differ between infants
who were exposed to NSAIDs in pregnancy and non-exposed
infants. However, this may have decreased our study power and
may have led to underestimation of our effect estimates, although
the total prevalence of major birth defects in our cohort (2.7%) is
comparable to the expected prevalence of 3% in most populations.
Conclusions
The findings of this large prospective cohort study showed no
associations between exposure to NSAIDs during the first part of
pregnancy and the risk of selected birth defects, although an
increased odds ratio was seen for septal defects after exposure the
multiple NSAIDs. This observation, based on only two exposed
cases, was not statistically significant and needs confirmation by
other studies. However, due to the small numbers of NSAID-
exposed infants for the individual birth defect categories, increases
in the risks of specific birth defects could not be excluded.
Supporting Information
Table S1 Characteristics of the 23 infants born with selected
birth defects after prenatal exposure to non-steroidal anti-
inflammatory drugs (NSAIDs).
(PDF)
Appendix S1 Results of the sensitivity analyses on the effect of
prenatal exposure to non-steroidal anti-inflammatory drugs
(NSAIDs) and selected birth defects.
(PDF)
Author Contributions
Conceived and designed the experiments: MMHJvG NR HN. Analyzed
the data: MMHJvG. Wrote the paper: MMHJvG. Interpretation of the
data: MMHJvG NR HN. Contributed to the writing of the paper:
MMHJvG NR HN. Acquisition of the data: HN.
References
1. Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg L, Olsen J, et al.
(1999) Drug use in first trimester and lactation: a population-based survey
among Danish women. Eur J Pharmacol 55: 139–144.
2. Glover DD, Amonkar M, Rybeck BF, Tracy TS (2003) Prescription, over-the-
counter, and herbal medicine use in a rural, obstetric population. Am J Obstet
Gynecol 188: 1039–1045.
3. Cleves MA, Savell VH, Jr., Raj S, Zhao W, Correa A, et al. (2004) Maternal use
of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs), and
muscular ventricular septal defects. Birth Defects Res A Clin Mol Teratol 70:
107–113.
4. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev
Pharmacol Toxicol 38: 97–120.
5. Cappon GD, Cook JC, Hurtt ME (2003) Relationship between cyclooxygenase 1
and 2 selective inhibitors and fetal development when administered to rats and
rabbits during the sensitive periods for heart development and midline closure.
Birth Defects Res B Dev Reprod Toxicol 68: 47–56.
6. Stanfield KM, Bell RR, Lisowski AR, English ML, Saldeen SS, et al. (2003)
Expression of cyclooxygenase-2 in embryonic and fetal tissues during organogen-
esis and late pregnancy. Birth Defects Res A Clin Mol Teratol 67: 54–58.
7. Ericson A, Ka¨lle´n BAJ (2001) Nonsteroidal anti-inflammatory drugs in early
pregnancy. Reprod Toxicol 15: 371–375.
8. Ka¨lle´n BAJ, Otterblad Olausson P (2003) Maternal drug use in early pregnancy
and infant cardiovascular defect. Reprod Toxicol 17: 255–261.
9. Ofori B, Oraichi D, Blais L, Rey E, Be´rard A (2006) Risk of congenital
anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested
case-control study. Birth Defects Res B Dev Reprod Toxicol 77: 268–279.
10. Nielsen GL, Sørensen HT, Larsen H, Pedersen L (2001) Risk of adverse birth
outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs:
population based observational study and case-control study. BMJ 322: 266–270.
11. Magnus P, Irgens LM, Haug K, Nystad W, Skjærven R, et al. (2006) Cohort
profile: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol
35: 1146–1150.
12. Nilsen RM, Vollset SE, Gjessing HK, Skjærven R, Melve KK, et al. (2009) Self-
selection and bias in a large prospective pregnancy cohort in Norway. Paediatr
Perinat Epidemiol 23: 597–608.
13. Irgens LM (2000) The Medical Birth Registry of Norway: epidemiological research
and surveillance throughout 30 years. Acta Obstet Gynecol Scand 79: 435–439.
14. ATC/DDD index 2010. Oslo: WHO Collaborating Centre for Drugs Statistics
Methodology, Available: http://www.whocc.no/atc_ddd_index/. Accessed
February 24, 2010.
15. International statistical classification of disease and related health problems, 10th
revision. Geneva: World Health Organization, Available: http://apps.who.int/
classifications/apps/icd/icd10online/. Accessed March 5, 2010.
16. Van Gelder MMHJ, van Rooij IALM, Miller RK, Zielhuis GA, de Jong-van den
Berg LTW, et al. (2010) Teratogenic mechanisms of medical drugs. Hum
Reprod Update 16: 378–394.
Prenatal NSAID Exposure and Birth Defects
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22174
17. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, et al.
(2003) Guidelines for case classification for the National Birth Defects Prevention
Study. Birth Defects Res A Clin Mol Teratol 67: 193–201.
18. Sheffield JS, Butler-Koster EL, Casey BM, McIntire DD, Leveno KJ (2002)
Maternal diabetes mellitus and infant malformations. Obstet Gynecol 100:
925–930.
19. Eriksson UJ, Cederberg J, Wentzel P (2003) Congenital malformations in
offspring of diabetic mothers – animal and human studies. Rev Endocr Metab
Disord 4: 79–93.
20. Li DK, Liu L, Odouli R (2003) Exposure to non-steroidal anti-inflammatory
drugs during pregnancy and risk of miscarriage: population based cohort study.
BMJ 327: 368–371.
21. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME (2006) Nonsteroidal
anti-inflammatory drugs during third trimester and the risk of premature closure
of the ductus arteriosus: a meta-analysis. Ann Pharmacother 40: 824–829.
22. Briggs GG, Freeman RK, Yaffe SJ (2008) Drugs in pregnancy and lactation: a
reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott
Williams & Wilkins.
23. Bateman DN, McElhatton PR, Dickinson D, Wren C, Matthews JN, et al.
(2004) A case control study to examine the pharmacological factors underlying
ventricular septal defects in the North of England. Eur J Clin Pharmacol 60:
635–641.
24. Werler MM, Bosco JLF, Shapira SK (2009) Maternal vasoactive exposures,
amniotic bands, and terminal transverse limb defects. Birth Defects Res A Clin
Mol Teratol 85: 52–57.
25. Werler MM, Mitchell AA, Moore CA, Honein MA (2009) Is there
epidemiologic evidence to support vascular disruption as a pathogenesis of
gastroschisis? Am J Med Genet Part A 149: 1399–1406.
26. Cassina M, De Santis M, Cesari E, van Eijkeren M, Berkovitch M, et al. (2010)
First trimester diclofenac exposure and pregnancy outcome. Reprod Toxicol 30:
401–404.
27. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, et al. (1999)
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-
2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc
Natl Acad Sci USA 96: 7563–7568.
28. Streck RD, Kunpf SW, Ozolinsˇ TRS, Stedman DB (2003) Rat embryos express
transcripts for cyclooxygenases-1 and carbonic anhydrase-4, but not for
cyclooxygenases-2, during organogenesis. Birth Defects Res B Dev Reprod
Toxicol 68: 57–69.
29. Cook JC, Jacobsen CF, Gao F, Tassinari MS, Hurtt ME, et al. (2003) Analysis of
the nonsteroid anti-inflammatory drug literature for potential developmental
toxicity in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 68: 5–26.
30. Lamers WH, Moorman AFM (2002) Cardiac septation: a late contribution of
the embryonic primary myocardium to heart morphogenesis. Circ Res 91:
93–103.
31. Vroom F, van den Berg PB, de Jong-van den Berg LTW (2008) Prescribing of
NSAIDs and ASA during pregnancy; do we need to be more careful? Br J Clin
Pharmacol 65: 275–276.
32. Damase-Michel C, Christaud J, Berrebi A, Lacroix I, Montastruc JL (2009)
What do pregnant women know about non-steroidal anti-inflammatory drugs?
Pharmacoepidemiol Drug Saf 18: 1034–1038.
33. Engeland A, Bramness JG, Kjersti Daltveit A, Rønning M, Skurtveit S, et al.
(2008) Prescription drug use among fathers and mothers before and during
pregnancy: a population-based cohort study of 106000 pregnancies in Norway
2004–2006. Br J Clin Pharmacol 65: 653–660.
34. Nohr EA, Frydenberg M, Henriksen TB, Olsen J (2006) Does low participation
in cohort studies induce bias? Epidemiology 17: 413–418.
35. Melve KK, Lie RT, Skjaerven R, van der Hagen CB, Gradek GA, et al. (2008)
Registration of Down syndrome in the Medical Birth Registry of Norway:
validity and time trends. Acta Obstet Gynecol Scand 87: 824–830.
36. Kubon C, Sivertsen A, Vindenes HA, A˚byholm F, Wilcox A, et al. (2007)
Completeness of registration of oral clefts in a medical birth registry: a
population-based study. Acta Obstet Gynecol Scand 86: 1453–1457.
Prenatal NSAID Exposure and Birth Defects
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22174
